Remdesivir and COVID-19 - Authors' reply

Affiliations

¹ Department of Pulmonary and Critical Care Medicine, Center of Respiratory Medicine, National Clinical Research Center for Respiratory Diseases, China-Japan Friendship Hospital, Beijing 100029, China; Institute of Respiratory Medicine, Chinese Academy of Medical Science, Beijing, China.
² Institute of Clinical Medical Sciences, China-Japan Friendship Hospital, Beijing 100029, China.
³ Tsinghua University School of Medicine, Beijing, China.
⁴ Department of Pulmonary and Critical Care Medicine, Center of Respiratory Medicine, National Clinical Research Center for Respiratory Diseases, China-Japan Friendship Hospital, Beijing 100029, China; Institute of Respiratory Medicine, Chinese Academy of Medical Science, Beijing, China; Tsinghua University-Peking University Joint Center for Life Sciences, Beijing, China; Institute of Respiratory Medicine, Chinese Academy of Medical Science, Peking Union Medical College, Beijing, China. Electronic address: caobin_ben@163.com.
⁵ Department of Pulmonary and Critical Care Medicine, Center of Respiratory Medicine, National Clinical Research Center for Respiratory Diseases, China-Japan Friendship Hospital, Beijing 100029, China; Institute of Respiratory Medicine, Chinese Academy of Medical Science, Beijing, China; Institute of Respiratory Medicine, Chinese Academy of Medical Science, Peking Union Medical College, Beijing, China.

Comment

Yeming Wang et al. Lancet. 2020.

. 2020 Oct 3;396(10256):954.

doi: 10.1016/S0140-6736(20)32015-8.

¹ Department of Pulmonary and Critical Care Medicine, Center of Respiratory Medicine, National Clinical Research Center for Respiratory Diseases, China-Japan Friendship Hospital, Beijing 100029, China; Institute of Respiratory Medicine, Chinese Academy of Medical Science, Beijing, China.
² Institute of Clinical Medical Sciences, China-Japan Friendship Hospital, Beijing 100029, China.
³ Tsinghua University School of Medicine, Beijing, China.
⁴ Department of Pulmonary and Critical Care Medicine, Center of Respiratory Medicine, National Clinical Research Center for Respiratory Diseases, China-Japan Friendship Hospital, Beijing 100029, China; Institute of Respiratory Medicine, Chinese Academy of Medical Science, Beijing, China; Tsinghua University-Peking University Joint Center for Life Sciences, Beijing, China; Institute of Respiratory Medicine, Chinese Academy of Medical Science, Peking Union Medical College, Beijing, China. Electronic address: caobin_ben@163.com.
⁵ Department of Pulmonary and Critical Care Medicine, Center of Respiratory Medicine, National Clinical Research Center for Respiratory Diseases, China-Japan Friendship Hospital, Beijing 100029, China; Institute of Respiratory Medicine, Chinese Academy of Medical Science, Beijing, China; Institute of Respiratory Medicine, Chinese Academy of Medical Science, Peking Union Medical College, Beijing, China.

No abstract available

Comment on

Remdesivir and COVID-19.
Dennis A. Dennis A. Lancet. 2020 Oct 3;396(10256):952. doi: 10.1016/S0140-6736(20)32022-5. Lancet. 2020. PMID: 33010830 Free PMC article. No abstract available.
Remdesivir and COVID-19.
Glaus MJ, Von Ruden S. Glaus MJ, et al. Lancet. 2020 Oct 3;396(10256):952. doi: 10.1016/S0140-6736(20)32021-3. Lancet. 2020. PMID: 33010831 Free PMC article. No abstract available.
Remdesivir and COVID-19.
Edwards JK, Cole SR, Adimora AA. Edwards JK, et al. Lancet. 2020 Oct 3;396(10256):953. doi: 10.1016/S0140-6736(20)32020-1. Lancet. 2020. PMID: 33010832 Free PMC article. No abstract available.
Remdesivir and COVID-19.
Wang LY, Cui JJ, Ouyang QY, Zhan Y, Guo CX, Yin JY. Wang LY, et al. Lancet. 2020 Oct 3;396(10256):953-954. doi: 10.1016/S0140-6736(20)32019-5. Lancet. 2020. PMID: 33010833 Free PMC article. No abstract available.

1. Wang Y, Zhang D, Du G. Remdesivir in adults with severe COVID-19: a randomised, double-blind, placebo-controlled, multicentre trial. Lancet. 2020;395:1569–1578. - PMC - PubMed
1. Sheahan TP, Sims AC, Graham RL. Broad-spectrum antiviral GS-5734 inhibits both epidemic and zoonotic coronaviruses. Sci Transl Med. 2017;9 - PMC - PubMed
1. de Wit E, Feldmann F, Cronin J. Prophylactic and therapeutic remdesivir (GS-5734) treatment in the rhesus macaque model of MERS-CoV infection. Proc Natl Acad Sci USA. 2020;117:6771–6776. - PMC - PubMed
1. Wang Y, Zhou F, Zhang D. Evaluation of the efficacy and safety of intravenous remdesivir in adult patients with severe COVID-19: study protocol for a phase 3 randomized, double-blind, placebo-controlled, multicentre trial. Trials. 2020;21:422. - PMC - PubMed
1. Shih WJ, Yao C, Xie T. Data monitoring for the Chinese clinical trials of remdesivir in treating patients with COVID-19 during the pandemic crisis. Ther Innov Regul Sci. 2020;54:1236–1255. - PMC - PubMed